Regenxbio Inc (NASDAQ: RGNX) kicked off on Monday, down -3.10% from the previous trading day, before settling in for the closing price of $8.07. Over the past 52 weeks, RGNX has traded in a range of $6.56-$28.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 111.76% over the last five years. While this was happening, its average annual earnings per share was recorded 21.56%. With a float of $44.68 million, this company’s outstanding shares have now reached $49.53 million.
The firm has a total of 344 workers. Let’s measure their productivity. In terms of profitability, gross margin is 39.46%, operating margin of -289.09%, and the pretax margin is -283.37%.
Regenxbio Inc (RGNX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Regenxbio Inc is 9.82%, while institutional ownership is 87.45%. The most recent insider transaction that took place on Dec 30 ’24, was worth 148,504. Before that another transaction happened on Oct 01 ’24, when Company’s Director sold 10,000 for $10.11, making the entire transaction worth $101,052. This insider now owns 11,286 shares in total.
Regenxbio Inc (RGNX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 21.56% per share during the next fiscal year.
Regenxbio Inc (NASDAQ: RGNX) Trading Performance Indicators
Take a look at Regenxbio Inc’s (RGNX) current performance indicators. Last quarter, stock had a quick ratio of 3.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.03, a number that is poised to hit -1.13 in the next quarter and is forecasted to reach -0.48 in one year’s time.
Technical Analysis of Regenxbio Inc (RGNX)
Analysing the last 5-days average volume posted by the [Regenxbio Inc, RGNX], we can find that recorded value of 0.83 million was lower than the volume posted last year of 1.14 million. As of the previous 9 days, the stock’s Stochastic %D was 56.45%. Additionally, its Average True Range was 0.61.
During the past 100 days, Regenxbio Inc’s (RGNX) raw stochastic average was set at 18.21%, which indicates a significant decrease from 56.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.54% in the past 14 days, which was lower than the 74.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.33, while its 200-day Moving Average is $11.47. Now, the first resistance to watch is $8.06. This is followed by the second major resistance level at $8.31. The third major resistance level sits at $8.58. If the price goes on to break the first support level at $7.54, it is likely to go to the next support level at $7.27. Now, if the price goes above the second support level, the third support stands at $7.02.
Regenxbio Inc (NASDAQ: RGNX) Key Stats
The company with the Market Capitalisation of 387.44 million has total of 49,545K Shares Outstanding. Its annual sales at the moment are 90,240 K in contrast with the sum of -263,490 K annual income. Company’s last quarter sales were recorded 24,200 K and last quarter income was -59,600 K.
